[HTML][HTML] Vascular cognitive impairment–Past, present, and future challenges
Vascular cognitive impairment (VCI) is a lifelong process encompassing a broad spectrum of
cognitive disorders, ranging from subtle or mild deficits to prodromal and fully developed …
cognitive disorders, ranging from subtle or mild deficits to prodromal and fully developed …
Clinical trials of new drugs for vascular cognitive impairment and vascular dementia
TTD Linh, YC Hsieh, LK Huang, CJ Hu - International journal of molecular …, 2022 - mdpi.com
Population aging has challenged the treatment of cognitive impairment or dementia.
Vascular dementia is the second leading cause of dementia after Alzheimer's disease …
Vascular dementia is the second leading cause of dementia after Alzheimer's disease …
Blood pressure variability and plasma Alzheimer's disease biomarkers in the SPRINT trial
Background: Recent observational studies suggest higher blood pressure (BP) variability
(BPV) is associated with Alzheimer's disease (AD) biomarkers amyloid-beta (Aβ) and tau …
(BPV) is associated with Alzheimer's disease (AD) biomarkers amyloid-beta (Aβ) and tau …
Looking behind the curtain: patient stratification according to genetic or demographic factors may yield unexpected results in studies of neurodegenerative diseases
FF Oliveira - Journal of Alzheimer's Disease, 2023 - content.iospress.com
Amyloid-PET studies of neurodegenerative diseases may yield inconclusive findings due to
lacking stratification according to genetic or demographic variants. APOE ɛ4 alleles are the …
lacking stratification according to genetic or demographic variants. APOE ɛ4 alleles are the …
Hepatopancreatic metabolic disorders and their implications in the development of Alzheimer's disease and vascular dementia
FI Pinheiro, I Araújo-Filho, ACM do Rego… - Ageing Research …, 2024 - Elsevier
Dementia has been faced with significant public health challenges and economic burdens
that urges the need to develop safe and effective interventions. In recent years, an …
that urges the need to develop safe and effective interventions. In recent years, an …
Research hotspots and trends of multimodality MRI on vascular cognitive impairment in recent 12 years: a bibliometric analysis
MH Xia, A Li, RX Gao, XL Li, Q Zhang, X Tong… - Medicine, 2022 - journals.lww.com
Background: Multimodality magnetic resonance imaging (MRI) is widely used to detect
vascular cognitive impairment (VCI). However, a bibliometric analysis of this issue remains …
vascular cognitive impairment (VCI). However, a bibliometric analysis of this issue remains …
Vascular oxidative stress causes neutrophil arrest in brain capillaries, leading to decreased cerebral blood flow and contributing to memory impairment in a mouse …
ABSTRACT INTRODUCTION In this study, we explore the role of oxidative stress produced
by NOX2-containing NADPH oxidase as a molecular mechanism causing capillary stalling …
by NOX2-containing NADPH oxidase as a molecular mechanism causing capillary stalling …
Association of glycemic variability with imaging markers of vascular burden, β-amyloid, brain atrophy, and cognitive impairment
Background and Objective We aimed to investigate the association between glycemic
variability (GV) and neuroimaging markers of white matter hyperintensities (WMH), beta …
variability (GV) and neuroimaging markers of white matter hyperintensities (WMH), beta …
Shedding Light on the Effects of Blood Pressure on Cognitive Decline and Dementia Risk by Way of Neurobiological Evidence
FF de Oliveira - Journal of Alzheimer's Disease, 2024 - content.iospress.com
Midlife cerebrovascular risk factors increase risk of late life cognitive impairment and
dementia, while their presence in patients with dementia may lead to cognitive improvement …
dementia, while their presence in patients with dementia may lead to cognitive improvement …
Pharmacogenetics of angiotensin modulators according to APOE-ϵ4 alleles and the ACE insertion/deletion polymorphism in Alzheimer's disease
Objective: In Alzheimer's disease (AD), angiotensin II receptor blockers (ARBs) could reduce
cerebrovascular dysfunction, while angiotensin-converting enzyme inhibitors (ACEis) might …
cerebrovascular dysfunction, while angiotensin-converting enzyme inhibitors (ACEis) might …